Licaminlimab

DB18936InvestigationalProtein Based Therapies

Licaminlimab is under investigation in clinical trial NCT05896670 (Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease).

Mechanism: Pharmacologically active on Tumor necrosis factor
Curator reviewed
Also known as: immunoglobulin scFv, anti-[Homo sapiens TNF (tumor necrosis factor, TNFSF2, DIF, TNF-alpha)], humanized monoclonal antibody single chain; IG scFv humanized single chain (V-KAPPA-VH) (1-254) [V-KAPPA (Homo sapiens IGKV1-5*03 (79.2%) -(IGHD) -IGKJ2*02 (77. · Immunoglobulin, anti-(human tumor necrosis factor α)(human-Oryctolagus cuniculus monoclonal ESBA1622 scFv fragment)
Code names: ESBA-1622 · LME-636 · OCS-02 · SS2X3Y9DGM

Resolves to

Compound

UNIID5ZJ707VIRCAS1688648-13-6

Targets

P01375TNF

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Licaminlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account